-
Key Brands
-
Statistics
-
Revenue
-
Contribution
-
Market data
| Aranesp | Imuran | Mounjaro® | Mybulen | Ridaq | Solpadeine |
|---|---|---|---|---|---|
| Anti-anaemic preparation | Immunosuppressant | GLP-1 agonist – diabetes and weight loss management | Analgesic anti-inflammatory | Diuretic | Opioid analgesic |
10
Products
Launched
Launched
(2024: 47)
0
Product
Recalls
Recalls
(2024: 7)
0
%
Average Staff
Turnover
Turnover
(2024: 9%)
0
Work-related
Facilities
Facilities
(2024: 1)
100
Sales
Representatives
Representatives
(2024: 237)
3919
Permanent
Employees
Employees
(June 2025)
2500
Permanent
Employees
Employees
(June 2024)
10
Products
Launched
Launched
(2022: 25)
0
Product
Recalls
Recalls
(2022: 1)
0
%
Average Staff
Turnover
Turnover
(2022: 13%)
Work-related
Facilities
Facilities
(2022: Nil)
100
Sales
Representatives
Representatives
(2022: 218)
2500
Permanent
Employees
Employees
(June 2022: 3,945)
| Revenue | 2025 R'million |
2024 (CER) R'million |
Change % |
|---|---|---|---|
| Commercial Pharmaceuticals | 10 086 | 8 914 | 13 |
| Prescription | 4 569 | 4 185 | 9 |
| Over the counter | 3 746 | 3 534 | 6 |
| Injectables | 1 771 | 1 195 | 48 |
| Manufacturing | 481 | 475 | 1 |
| Finished dose form | 250 | 210 | 19 |
| Active pharmaceutical ingredients | 231 | 265 | (13) |
| Total | 10 567 | 9 389 | 13 |
Note: Commercial Pharmaceuticals' revenue is by customer geography and Manufacturing revenue is by place of manufacture.
CER: Constant Exchange Rate
CER: Constant Exchange Rate
Contribution to Group revenue (%)
2025
Rest of Group
76
Africa Middle East
24
Revenue by segment (%)
2025
Prescription
43
Over the counter
36
Injectables
17
Active pharmaceutical ingredients
2
Finished dose form
2
- Aspen is the leading pharmaceutical company in South Africa, ranked first in the private, prescription*, and public sector markets; second in over the counter (“OTC”); and the only local manufacturer recently awarded a tender for antiretroviral medication.
- Aspen has a proven track record of growing multinational partnerships with leading companies, including Eli Lilly, Amgen, GlaxoSmithKline, Vifor, Bayer, Roche, and recently with Boehringer Ingelheim through a long-term distribution and promotional agreement.
- Mounjaro® is the fastest product to reach R100 million in South African pharmaceutical history, driving 133% GLP-1 market growth with Aspen holding a 41% value share¹. KwikPen® approval to meet demand, with chronic weight loss management indication, has been approved by the South African Health Products Regulatory Authority.
Source: Qlik Sense TPMG, June 2025; DVISAG, Q1 2024. IQVIA Monthly Market Feedback Report, June 2025 data period.
¹ National South Africa IQVIA TPM, June 2025 GLP-1 market excluding Saxenda.
- The South African private pharmaceutical sector was valued at R54,5 billion MAT# for the period ended June 2023.
- Aspen has the second highest market share by value within the South African private sector, at 9,4%.
- By 2025, Middle East & Africa pharmaceutical market is collectively estimated to be USD56 billion, with United Arab Emirates and Egypt contributing 24,0% and 17,4% respectively.
- Middle East, North Africa & Turkey pharmaceutical market is expected to grow by 4,6% compound annual growth rate from 2021 to 2024, driven mainly by Turkey and Egypt.
Source: IQVIA June 2023. Sources: IQVIA TPM Moving Annual Total June 2022, IQVIA Middle East & Africa Pharmaceutical Market Insights. Released June 2022.
* Moving annual total (“MAT”).
